Pictet Asset Management Holding SA Purchases 3,431 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Pictet Asset Management Holding SA boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 27.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 15,969 shares of the biopharmaceutical company’s stock after buying an additional 3,431 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Catalyst Pharmaceuticals were worth $333,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Catalyst Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after acquiring an additional 390,116 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Catalyst Pharmaceuticals by 5.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after purchasing an additional 151,495 shares during the last quarter. Boston Partners boosted its stake in Catalyst Pharmaceuticals by 1.3% in the 4th quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock worth $27,325,000 after purchasing an additional 16,601 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Catalyst Pharmaceuticals by 6.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock valued at $26,023,000 after purchasing an additional 79,182 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Catalyst Pharmaceuticals by 80.3% during the 4th quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company’s stock valued at $15,364,000 after purchasing an additional 327,936 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Activity

In related news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $21.45 on Friday. The company has a market cap of $2.61 billion, a price-to-earnings ratio of 18.18, a P/E/G ratio of 3.31 and a beta of 0.79. The business’s 50-day moving average is $22.65 and its two-hundred day moving average is $21.99. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Robert W. Baird boosted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Finally, Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.